Skip to main content
. 2020 Aug 27;37:101702. doi: 10.1016/j.redox.2020.101702

Fig. 1.

Fig. 1

The expression of NRF2 and FOCAD in human NSCLC tissues. The cancer tissues and paracancer tissues from 6 NSCLC patients (Patient-001 to Patient-006) were harvested for NRF2 and FOCAD via IHC staining (A). In the negative control, non-specific IgG was used to replace the first antibody. The cancer slice from patient-001 was used in the negative control of NRF2 staining (A1), and the paracancer slice from patient-001 was used in the negative control of FOCAD staining (A2). The relative intensity of NRF2 (B) and FOCAD (C) were calculated respectively, and the level in Cancer group was considered as “1”. Results were expressed as mean ± SD, and the P value less than 0.05 was considered statistically significant. *: P < 0.05 compared between cancer tissue and paracancer.